Clinical observation of artificial tears combined with Tuina in the treatment of dry eye disease

Clinical observation and tear proteomics study of massage combined with artificial tears in the treatment of dry eye disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2024000001

Enrollment

Unknown

Registered

2024-01-03

Start date

2024-01-20

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry eye disease

Interventions

The artificial tears group:The patient was instructed to use sodium hyaluronate eye drops three times a day for a total of 4 weeks. During the intervention period, patients performed sham tuina manipu

The AT combined with Tuina group:On the basis of sodium hyaluronate eye drops combined with massage treatment, the application of sodium hyaluronate was the same as artificial tears group. The doctor

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria are as follows: (1) Patients aged 18-80 years, male or female. (2) Meet the diagnostic criteria for DED. (3) Have not participated in any other drug clinical trials in the past 3 months. (4) Informed about this study and signed an informed consent form, voluntarily participating in this clinical trial research.

Exclusion criteria

Exclusion criteria: The exclusion criteria are as follows: (1) patients with serious systemic diseases such as heart, brain, liver, kidney and blood system. (2) patients with Sjogren's syndrome; (3) patients with congenital organ dysfunction. (4) Lacrimal gland obstruction caused by ocular surface injury. (5) Severe meibomian gland dysfunction and other active eye diseases affected clinical observers. (6) wearing contact lenses for a long time. (7) patients with recent eye surgery. (8) Use of systemic antihistamines, anticholinergic drugs, or other hormones that interfere with the efficacy in the past 3 months; (9) patients with sensitive constitution who could not tolerate the drugs used in this study. (10) patients who could not adhere to the treatment.

Design outcomes

Primary

Measure	Time frame
Ocular surface disease index;	—

Secondary

Measure	Time frame
Fluorescein break up time;Schirmer I test;Quality of life;Corneal fluorescein staining;Overall recovery;Assessment of ocular pain;	—

Countries

China

Contacts

Public ContactWu Lei

Jiangsu Haibin Sanatorium

270762@njucm.edu.cn+86 180 8207 7337

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026